Targeting CDK4: The Therapeutic Potential of AU2-94 in Combating Cancer

3 June 2024
Cyclin-dependent kinases play a crucial role in cellular development, and specific CDK4/6 inhibitors have been shown to extend the lifespan of certain breast cancer patients. However, these drugs have limitations due to off-target effects, leading to reduced dosages and treatment interruptions, which can build resistance and compromise their efficacy. A new compound, AU2-94, has been identified as a highly selective CDK4 inhibitor with potential for treating various CDK4-dependent cancers, including different types of breast cancer, colorectal cancer, and glioblastoma.

AU2-94 demonstrates a high level of specificity for CDK4 with a Ki of 2 nM, significantly lower than that for CDK6 at 279 nM. It effectively halts the cell cycle in the G1 phase and curbs the proliferation of cancer cells. Notably, AU2-94 also reduces the levels of CDK2, Cyclin E2, Cyclin A2, and Cyclin B1, and triggers apoptosis by lowering Bcl-2 and FOXM1 levels. In contrast to its impact on cancer cells, it has minimal effects on the cell cycle, senescence, or apoptosis in human bone marrow cells, and unlike existing CDK4/6 inhibitors, it does not reduce the counts of lymphocytes and neutrophils.

In in vivo tumor models, AU2-94 has shown high efficacy, causing tumor regression in ER+ breast cancer xenografts and an 86% tumor-free rate in a specific model of luminal breast cancer. In colorectal cancer xenografts, it significantly inhibited tumor growth in a dose-dependent manner without overt toxicity. Pharmacokinetic and pharmacodynamic studies indicate a 500-fold higher concentration of AU2-94 in tumors compared to plasma, highlighting its tumor-targeting specificity. Several robust biomarkers and pharmacodynamic markers were identified, and AU2-94 has shown promise in crossing the blood-brain barrier, reducing tumor burden, and improving survival in glioblastoma models.

Furthermore, AU2-94 has been found to enhance the anti-cancer effects of PI3K/Akt/mTOR and HER2 inhibitors when used in combination. It is a CDK4 inhibitor with high selectivity against a panel of 360 human kinases, which may contribute to its better safety profile compared to existing CDK4/6 inhibitors. With its high oral bioavailability, potent antitumor activity, and favorable safety profile, AU2-94 is a promising candidate for clinical development.

How to Use Synapse Database to Search and Analyze Translational Medicine Data?

The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

图片包含 应用程序

描述已自动生成

Click on the image below to go directly to the Translational Medicine search interface.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成